Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

The FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy ...

A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in ...

Oncorena, a Swedish pharma company, announced that the US FDA has approved the company’s IND application to initiate the phase I/II study Oncorella-1: A phase 1/2, open label, single arm study on ...

SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...

Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma (mRCC), even in patients who have coexisting acute kidney injury (AKI) or ...

We selected 71,414 kidney cancer patients from SEER database ... (8120), papillary transitional cell carcinoma (8130), papillary adenocarcinoma (8260), clear-cell adenocarcinoma (8310), renal cell ...

National Kidney Foundation. Kidney Numbers and the CKD Heat Map. University of Rochester Medical Center. Health Encyclopedia. Blood urea nitrogen. Pottel H, Delanaye P, Cavalier E. Exploring Renal ...

in the obstructed kidney an acute pyelonephritis with necrosis of the renal papillae, as well as cortical abscesses, was found — the exact analogue of the lesion found in the nondiabetic group ...